Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
07:05am, Tuesday, 05'th May 2026
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNew
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months
03:45pm, Monday, 04'th May 2026
The Street is bullish on this biotech's prospects, but is the sentiment justified?
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge
10:45am, Friday, 01'st May 2026
Buy the story, sell the news. That's a reasonable explanation for why Viking Therapeutics NASDAQ: VKTX fell over 3% the day the company delivered its Q1 2026 earnings report.
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs
12:31pm, Thursday, 30'th Apr 2026
Viking Therapeutics posts a wider Q1 loss as R&D spend jumps on Phase III obesity drug work, while it advances VK2735 studies and preps oral late-stage study.
Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard
08:53am, Thursday, 30'th Apr 2026
Viking Therapeutics, Inc. remains a hold as competitive pressure mounts in the GLP-1 obesity/diabetes space, with its lead VK2735 candidate lagging larger peers. VKTX's Phase 3 VANQUISH studies are fu
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
03:01am, Thursday, 30'th Apr 2026
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call Transcript
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 29'th Apr 2026
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral
Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?
11:16am, Tuesday, 28'th Apr 2026
Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of “Moderate Buy” by Analysts
02:38am, Monday, 27'th Apr 2026
Shares of Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen ratings firms that are presently covering the company, Mar
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street
10:02am, Sunday, 26'th Apr 2026
Although now mature, the weight-loss drug market remains strong and growing. The top GLP-1 drug competitors were first to market, but not racing to the finish line has given some drug developers more
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
06:51pm, Thursday, 23'rd Apr 2026
Viking Therapeutics, Inc. (VKTX) closed at $32.8 in the latest trading session, marking a -4.23% move from the prior day.
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
04:35pm, Wednesday, 22'nd Apr 2026
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopha
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to Expect
09:36am, Tuesday, 21'st Apr 2026
VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key obesity drug developments.
Better Long-Term Buy: Eli Lilly or Viking Therapeutics?
04:44pm, Friday, 17'th Apr 2026
Eli Lilly has been a growth beast, coming off an impressive year in which its revenue rose by 45%. Viking Therapeutics has an exciting GLP-1 drug in development that, if approved, could send its share
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
05:10am, Friday, 17'th Apr 2026
Viking Therapeutics aims to participate in the billion-dollar obesity market. The company's most advanced candidate is in a phase 3 trial.
